PMV Pharmaceuticals grants 319,270 options to COO

PMV Pharmaceuticals reported that its General Counsel & COO, Robert Ticktin, received a grant of 319,270 employee stock options.

Rhea-AI Filing Summary

PMV Pharmaceuticals reported that its General Counsel & COO, Robert Ticktin, received a grant of 319,270 employee stock options. These options give him the right to buy PMV Pharmaceuticals stock in the future, rather than representing shares bought on the open market.

The options were granted at an exercise price listed as $0.0000 per share in the filing and will vest over time. According to the footnote, the award vests in 48 equal monthly installments beginning on April 3, 2026, meaning the executive gains the right to exercise portions of the grant gradually over four years.

Insider Trade Summary

Grant/Award: 319,270 shares

Grant/Award 1 txn

Insider Ticktin Robert

Role General Counsel & COO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	319,270	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 319,270 contracts (Direct)

Footnotes (1)

1. F1. Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PMV Pharmaceuticals (PMVP) report for Robert Ticktin?

PMV Pharmaceuticals reported that General Counsel & COO Robert Ticktin received a grant of 319,270 employee stock options. These options are a compensation award, not an open-market stock purchase or sale, and give him the right to buy company shares in the future.

How many stock options were granted to the PMVP General Counsel & COO?

Robert Ticktin, PMV Pharmaceuticals’ General Counsel & COO, was granted 319,270 employee stock options. This entire amount is reported as held directly after the transaction, reflecting a single compensation award rather than multiple separate transactions or open-market trades.

What is the vesting schedule for Robert Ticktin’s PMVP stock options?

The 319,270 PMV Pharmaceuticals stock options granted to Robert Ticktin vest in 48 equal monthly installments. Vesting starts on April 3, 2026, which means the award effectively vests over four years, with a portion becoming exercisable each month during that period.

Was the PMVP insider transaction a stock purchase or a compensation award?

The PMV Pharmaceuticals Form 4 shows a compensation award, not a market purchase. Robert Ticktin received an Employee Stock Option grant coded as an acquisition (grant/award), giving him rights to buy shares later rather than buying existing shares in the market.

Does Robert Ticktin hold the PMVP options directly or through another entity?

The filing reports Robert Ticktin’s ownership of the 319,270 employee stock options as direct. There is no footnote indicating that another entity, such as a trust or LLC, holds these options or exercises separate voting or investment authority over them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 04:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticktin Robert

(Last) (First) (Middle)

C/O PMV PHARMACEUTICALS, INC.

400 ALEXANDER PARK DRIVE, SUITE 301

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel & COO

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.53	03/05/2026		A		319,270		(1)	03/05/2035	Common Stock	319,270	$0	319,270	D

Explanation of Responses:

1. Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2026.

	/s/ Robert Ticktin	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.